Neuro Emergencies: Intracerebral Hemorrhage Flashcards

(55 cards)

1
Q

Small Vessel Disease Types
Arteriolosclerosis what is it and where does it affect?

A

Concentric hyalinized vascular wall thickening favoring the penetrating arterioles of the basal ganglia, thalamus, brainstem, and deep cerebellar nuclei

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Small Vessel Disease Types
Arteriolosclerosis
Risk Factors

A

HTN
DM
Age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Small Vessel Disease Types
Cerebral Amyloid Angiopathy (CAA) What is it and where does it affect?

A

Deposition primarily of the Beta-amyloid peptide in the walls of arterioles and capillaries in the leptomeninges, cerebral cortex, and cerebellar hemispheres

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Small Vessel Disease Types
Cerebral Amyloid Angiopathy (CAA)
Risk Factors

A

Age
apolipoprotein E genotypes containing the ε2 or ε4 alleles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mechanisms of ICH - Related Brain Injury
Direct pressure effects what?

A

Local compression of immediately surrounding brain parenchyma
Perilesional edema
Increase ICP
Hydrocephalus
Herniation
Hematoma Expansion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mechanisms of ICH - Related Brain Injury
Secondary physiological and cellular pathways

A

Biochemical toxicity of blood products such as hgb, iron and thrombin (exact mechanism is unknown)
Cerebral edema
Inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Typical Hypertensive ICH Locations
50% occur where?
35% occur where?
10% occur where?
6% occur where?

A

deep
lobar
cerebellar
brainstem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ICH risk factors include?

A

Anticoagulation
Bleeding d/o
Older age
Cerebral amyloid angiopathy (CAA)
AVM/Aneurysm/dural arteriovenous malformations/cavernous
Cerebral venous thrombosis
Tobaccos use
Renal or liver failure
Recent CEA
Cerebral neoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ICH vascular risk factors include?

A

Ischemic stroke
Prior ICH
HTN
DM
Metabolic Syndrome
HLD
Imaging biomarkers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clinical Manifestations of ICH include?

A

HA common but not always present
N/V
Onset of sudden focal deficit w/ or w/o progression
AMS
ECG changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Clinical Evaluation of ICH includes?

A

ABCs
Neuro assessment
Physical Exam
Onset/Last known normal
Focused Hx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Clinical Evaluation of ICH
Focused Hx includes?

A

PMH
Medications
Cognitive impairment or dementia
Social hx (substance abuse)
Liver disease, uremia, malignancy and hematologic d/o

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Clinical Evaluation of ICH
Labs to order include?

A

CBC
PT/INT & aPTT
CMP
blood glucose
troponin
ECG
Tox screen
ESR
CRP
pregnancy test

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Clinical Evaluation of ICH
Specific test for DOACs?

A

dilute thrombin time
anti-Xa activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clinical Evaluation of ICH
Imaging?

A

Head CT or MRI
CTA w/n first few hrs may be reasonable to identify pts at risk for hematoma expansion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

CTA plus consideration of CTV or MRI w/ MRA is recommended in which patient populations?

A

Pts w/ lobar spontaneous ICH and age < 70
Pt w/ deep/posterior fossa spontaneous ICH and age < 45
Pts w/ deep posterior fossa age 45-70 w/o history of HTN and signs of small vessel disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

CTA plus consideration of CTV or MRI w/ MRA is used to evaluate for what?

A

macrovascular cause including:
AVM
aneurysm
dural arteriovenous fistula
cavernoma
cerebral venous thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Clinical Evaluation
Digital Subtraction Angiography should be used in patient w/?

A

spont. IVH and no detectable parenchymal hemorrhage
spont. ICH and a CTA or MRA suggestive of macrovascular causes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Clinical Evaluation
Initial scans should measure what?

A

Initial ICH volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ICH Volume
How to Calculate
AxBxC/2
A=?
B=?
C=?

A

A= greatest hemorrhage diameter in the axial plane
B= hemorrhage diameter at 90* to A in the axial plane
C= the number of CT slices with the hemorrhage multiplied by slice thickness
Divide by 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How to Calculate an ICH score?

A

Add points from:
GCS score at presentation
ICH volume
IVH
Origin of ICH
Age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

ICH Score
GCS score at presentation
13-15 =?
5-12 =?
3-4 =?

A

0
1
2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

ICH Score
ICH volume (cm3)
>/=30 =?
<30 =?

24
Q

ICH Score
IVH
Yes =?
No =?

25
ICH Score Origin of ICH Infratentorial =? Supratentorial =?
1 0
26
ICH Score Age >/= 80 =? <80 =?
1 0
27
ICH Management Acute Blood Pressure lowering Careful titration should be used to ensure what? Should avoid what? Initiate treatment wi/n what timeframe? reaching target w/n how long?
continuous smooth and sustained control of BP Avoid peaks and large variability in SBP 2hrs of onset of ICH; 1hr
28
ICH Management Acute Blood Pressure lowering For ICH patient presenting w/ SBP between 150 and 220 mmHg acute lower of SBP to a target of what is safe?
140 mmHg w/ a goal of maintaining SBP 130-150 mmHg
29
ICH Management Acute Blood Pressure lowering In patients w/ mild to moderate ICH presenting w/ SBP > 150 mmHg, acute lowering to what SBP is potentially harmful?
< 130 mmHg
30
Management of Anticoagulation Reversal Warfarin For patients requiring large volume resuscitation consider what? Reversal agent and dose? reversal based on INR?
FFP 15-20mL/kg Vitamin K 10mg IVPB 4 factor PCC based on INR
31
Management of Anticoagulation Reversal Warfarin 4-factor PCC based on INR, dosage for: INR 2-3.9 INR 4-6 INR >6
25 u/kg (max 2500u) 35 u/kg (max 3500u) 50 u/kg (max 5000u)
32
Management of Anticoagulation Reversal DOACs Factor Xa inhibitors get reversed w/?
PCC 50 u/kg (max 5000u) Andexant alpha
33
Management of Anticoagulation Reversal DOACs Direct thrombin inhibitors get reversed w/?
Activated charcoal 50g (if last dose w/n 2hrs) Idarucizumab 5g IVP
34
Management of Anticoagulation Reversal Heparin or LMWH get reversed w/?
Protamine 1mg for each 100 u of heparin admin in the last 2 hr (max dose 50mg) Protamin 1 mg for each 1 mg of Enoxaparin (max 50mg)
35
Management of Anticoagulation Reversal Factor VIIa provides a reduction in? Clinical outcome differences? Risk of?
hematoma expansion no difference thromboembolic events
36
Management of Anticoagulation Reversal Dabigatran Taken w/n 2 hrs? Is Idarucizumab available: Yes? No?
Activated charcoal 50 g Yes - give 5g IVP No - PCCs or aPCC and or renal replacement therapy
37
Management of Anticoagulation Reversal Factor Xa - inhibitors Taken w/n 2 hrs? Is andexanet alfa available: Yes? No?
Activated charcoal 50 g Yes - give it No - 4 Factor PCC or aPCC
38
Anitplatelet-Related Hemorrhage Pt w/ spont. ICH being treated w/ ASA who require emergency surgery, what might be considered?
platelet transfusion
39
Anitplatelet-Related Hemorrhage Pt w/ spont. ICH being treated w/ ASA not scheduled for emergent neurosurgery platelet transfusions are what?
potentially harmful and should not be administered
40
General Inpatient Management Prompt transfer to ICU/SDU should be initiated for what?
Neuro assessments Intubation if indicated Analgesia if indicated Cardiac monitoring SMART consult NSGY consult
41
General Inpatient Management Treatment of elevated ICP includes
Simple measures Aggressive measures 1. Hyperosmolar therapy 2. EVD placement (hydrocephalus, thrombolytic) 3. Hematoma Evac
42
Surgical treatment Which patient should undergo surgical removal of cerebellar hemorrhages?
Cerebellar hemorrhages w/ neurologic deterioration brainstem compression and/or hydrocephalus from ventricular obstruction have cerebellar ICP > 15mL
43
Surgical treatment Supratentorial hematoma evac in deteriorating pts might be considered as a life-saving measure when ICH volume =? or GCS is what?
> 20-30 mL 5-12
44
Surgical Treatment DC w/ or w/o hematoma evac might reduce mortality for patient w/ what?
supratentorial ICH who are in a coma have large hematomas w/ significant midline shift have elevated ICP refractory to medical management
45
General Inpatient Management Glucose Control Goals
Treat hypoglycemia (<40-60 mg/dL) Maintain BG < 180 mg/dL
46
General Inpatient Management Fever control should target a temp > what?
37.5*C
47
General Inpatient Management When should steroids be used?
NO STEROIDS
48
General Inpatient Management When to give Anti-Seizure Medications?
Treat clinical and electrographic seizures No prophylactic AEDs
49
General Inpatient Management Prior to discharge BP should be lowered to what? and why?
130/80 mmHg to prevent hemorrhage recurrence
50
General Inpatient Management When should rehabilitation start?
Early (24-48 hrs after onset)
51
General Inpatient Management Screenings to consider?
Dysphagia Depression/Anxiety Cognitive
52
General Inpatient Management DVT prophylaxis should include?
SCDs No graduated compression stockings UFH or LMWH 24-48 hrs from onset IVC for DVT
53
General Inpatient Management Consider long term antithrombotic therapy in patients with? What to consider? May be safe when?
A-fib/DVT/Mechanical valve/LVAD Risk vs Benefit 2-8 wks after ICH
54
General Inpatient Management Avoid regular long-term use of what?
NSAIDs
55
General Inpatient Management In pts w/ spont. ICH and an established indication for statin pharmacotherapy, the risk and benefits of statin therapy on ICH outcomes and recurrence relative to overall prevention of cardiovascular events are what?
uncertain